RACE (rate vs rhythm control) 2002

1 Treatments

Studied treatment Rate control (rate slowing medication and anticoagulation)

Control treatment Rhythm control: serial cardioversions and antiarrhythmic drugs and oral anticoagulants

Concomittant treatments -

Age (yr) 68 y

Female (%) 36.6 %

Rate-control targets achieved -

Resting heart-rate target achieved -

Exercise heart-rate target achieved -

2 Patients

Patients patients with persistent atrial fibrillation after a previous electrical cardioversion

Inclusion criteria -

Exclusion criteria -

heart failure 50%

Duration of permanent atrial fibrillation -

Duration of any atrial fibrillation -

CHADS2 score 3-6 -

CHADS2 score 2 -

CHADS2 score 0-1 -

Heart rate at rest -

Left ventricular ejection fraction -

3 Methods

Blinding open
**Design**  Parallel groups

**Centers**  -

**Geographical area**  -

**Sizes**  256/266

### 4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>death by cardiac arrhythmia</td>
<td>-/256</td>
<td>-/266</td>
<td>NA</td>
</tr>
<tr>
<td>combined endpoint</td>
<td>24/256</td>
<td>32/266</td>
<td>0,78</td>
</tr>
<tr>
<td>major bleedings</td>
<td>12/256</td>
<td>9/266</td>
<td>1,39</td>
</tr>
<tr>
<td>CV death</td>
<td>-/256</td>
<td>-/266</td>
<td>NA</td>
</tr>
<tr>
<td>Atrial fibrillation follow-up</td>
<td>230/256</td>
<td>163/266</td>
<td>1,47</td>
</tr>
<tr>
<td>hospitalisations (excluding those for cardioversion)</td>
<td>134/256</td>
<td>113/266</td>
<td>1,23</td>
</tr>
<tr>
<td>death</td>
<td>21/256</td>
<td>19/266</td>
<td>1,15</td>
</tr>
<tr>
<td>stroke/TIA</td>
<td>13/256</td>
<td>19/266</td>
<td>0,71</td>
</tr>
<tr>
<td>Peripheral embolism</td>
<td>1/256</td>
<td>2/266</td>
<td>0,52</td>
</tr>
</tbody>
</table>

### 5 References